Nanoencapsulated curcumin and praziquantel treatment reduces periductal fibrosis and attenuates bile canalicular abnormalities in Opisthorchis viverrini-infected hamsters

Simple item page
dc.contributor.authorLakhanawan Charoensuk
dc.contributor.authorPorntip Pinlaor
dc.contributor.authorSupason Wanichwecharungruang
dc.contributor.authorKitti Intuyod
dc.contributor.authorKulthida Vaeteewoottacharn
dc.contributor.authorApisit Chaidee
dc.contributor.authorPuangrat Yongvanit
dc.contributor.authorChawalit Pairojkul
dc.contributor.authorNatthakitta Suwannateep
dc.contributor.authorSomchai Pinlaor
dc.contributor.correspondenceS. Pinlaor; Department of Parasitology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; email: psomec@kku.ac.th
dc.date.accessioned2025-03-10T07:36:30Z
dc.date.available2025-03-10T07:36:30Z
dc.date.issued2016
dc.description.abstractThis study investigated the effects of nanoencapsulated curcumin (NEC) and praziquantel (PZQ) treatment on the resolution of periductal fibrosis (PDF) and bile canalicular (BC) abnormalities in Opisthorchis viverrini infected hamsters. Chronic O. viverrini infection (OV) was initially treated with either PZQ (OP) and subsequently treated with NEC (OP + NEC), curcumin (OP + Cur) or unloaded carriers (OP + carrier) daily for one month. OP + NEC treatment reduced the PDF by suppression of fibrotic markers (hydroxyproline content, _-SMA, CTGF, fibronectin, collagen I and III), cytokines (TGF-_ and TNF-_) and TIMP-1, 2, 3 expression and upregulation of MMP-7, 13 genes. Higher activity of NEC in reducing fibrosis compared to curcumin was also demonstrated in in vitro studies. Moreover, OP + NEC also prevented BC abnormalities and upregulated several genes involved in bile acid metabolism. These results demonstrate that NEC and PZQ treatment reduces PDF and attenuates BC defect in experimental opisthorchiasis. From the Clinical Editor: Infection by Opisthorchis viverrini leads to liver fibrosis and affects population in SE Asia. Currently, praziquantel (PZQ) is the drug of choice but this drug has significant side effects. In this study, the authors combined curcumin (NEC) and praziquantel in a nanocarrier to test the anti-oxidative effect of curcumin in an animal model. The encouraging results may pave a way for better treatment in the future. � 2015 Elsevier Inc.
dc.identifier.citationNanomedicine: Nanotechnology, Biology, and Medicine
dc.identifier.doi10.1016/j.nano.2015.10.005
dc.identifier.issn15499634
dc.identifier.scopus2-s2.0-84957060235
dc.identifier.urihttps://repository.dusit.ac.th//handle/123456789/4828
dc.languageEnglish
dc.publisherElsevier Inc.
dc.rights.holderScopus
dc.subjectBile canalicular abnormalities
dc.subjectNanoencapsulated curcumin
dc.subjectOpisthorchis viverrini
dc.subjectPeriductal fibrosis
dc.subjectPraziquantel
dc.titleNanoencapsulated curcumin and praziquantel treatment reduces periductal fibrosis and attenuates bile canalicular abnormalities in Opisthorchis viverrini-infected hamsters
dc.typeArticle
mods.location.urlhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84957060235&doi=10.1016%2fj.nano.2015.10.005&partnerID=40&md5=7c795caa842435688a4dea35d4fd2a48
oaire.citation.endPage32
oaire.citation.issue1
oaire.citation.startPage21
oaire.citation.volume12
Files
Collections
SCOPUS 2015-2019